The role of intravenous iron in anemia management and transfusion avoidance. (odpre novo okno)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Vir‎: Transfusion 2008;48(5):988-1000.

Indeksirano‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (odpre novo okno)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (odpre novo okno)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Vir‎: BJU Int 2011;108(10):1582-7.

Indeksirano‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (odpre novo okno)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (odpre novo okno)

Lepor H, Lipkin M, Slova D.

Vir‎: Urology 2010;75(6):1424-8.

Indeksirano‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (odpre novo okno)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (odpre novo okno)

Nieder AM, Rosenblum N, Lepor H.

Vir‎: Urology 2001;57(4):737-41.

Indeksirano‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (odpre novo okno)